The Original Investigation titled “Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes,” published in the April 14, 2020, issue of JAMA, included errors in the Results section. This included labeling weight decline in those with diabetes as weight decline in those without diabetes at 8 months, citing reference 18 rather than reference 16 in footnote “b” in Table 2, and not indicating that the absolute difference in cardiovascular death or hospitalization for heart failure among patients with diabetes was presented as a percentage in Table 2. The text and table have been corrected. (All other information in the Results is correct and remains unchanged.)
